# US 2019/0375836 A1 · Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375836 A1
- Document ID: US20190375836A1
- Status: Published application
- Kind: A1
- Application number: 16/540,388
- Filed: 2019-08-14
- Published: 2019-12-12
- Earliest claimed: 2016-02-05
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Joseph Hedrick; Elizabeth C. Hsia; Paul Imm; Jocelyn Leu; Bethany Paxson; Mark Rigby; Songmao Zheng; Ramineh Zoka
- Web page: https://patentgrep.com/patent/US20190375836A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61M 5/003: {Kits for diabetics}
- A61M 5/31533: {Dosing mechanisms, i.e. setting a dose (administrating mechanisms A61M5/31565)}
- A61M 5/31573: {Accuracy improving means}
- A61M 5/31591: {Single dose, i.e. individually set dose administered only once from the same medicament reservoir, e.g. including single stroke limiting means}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/565: Complementarity determining region [CDR]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the treatment or prevention of Type I Diabetes (T1D).

## Claims

### Claim at position 1

1-101. (canceled)

### Claim 102

At least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the treatment or prevention of Type I Diabetes.

### Claim 103

(canceled)

### Claim 104

(canceled)

### Claim 105

(canceled)

### Claim 106

A method for treating pre-Type 1 Diabetes (pre-T1D) in a human subject, wherein the subject is 6 to 21 years of age and has ≥2 auto-antibodies for T1D, and wherein said pre-T1D is prior to onset of symptoms and requirement for exogenous insulin, the method comprising administering to the subject an anti-TNF antibody having a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO:36 and a light chain (LC) comprising an amino acid sequence of SEQ ID NO:37, wherein said anti-TNF antibody is administered with a medical device suitable for self-administration, and wherein the device is a prefilled syringe with an ULTRASAFE PASSIVE® (needle guard) if the subject weighs ≥45 kg and VARIOJECT™ (injector) if the subject weighs <45 kg.

### Claim 107 (depends on 106)

The method according to claim 106, wherein the device is the VARIOJECT™ (injector) with a 4.5 mm needle length.

### Claim 108

A composition comprising at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37, and at least one pharmaceutically acceptable carrier or diluent for use in the treatment or prevention of Type I Diabetes.

### Claim at position 9



### Claim 110

(canceled)

### Claim 111

(canceled)

### Claim 112

(canceled)

### Claim 113

A method for treating pre-Type 1 Diabetes (pre-T1D) in a human subject, wherein the subject is 6 to 21 years of age and has ≥2 auto-antibodies for T1D, and wherein said pre-T1D is prior to onset of symptoms and requirement for exogenous insulin, the method comprising administering to the subject a composition comprising an anti-TNF antibody having a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO:36 and a light chain (LC) comprising an amino acid sequence of SEQ ID NO:37, wherein said composition is administered with a medical device suitable for self-administration, and wherein the device is a prefilled syringe with an ULTRASAFE PASSIVE® (needle guard) if the subject weighs ≥45 kg and VARIOJECT™ (injector) if the subject weighs <45 kg.

### Claim 114 (depends on 112)

The method according to claim 112, wherein the device is the VARIOJECT™ (injector) with a 4.5 mm needle length.

### Claim 115

A method for treating pre-Type I Diabetes (pre-T1D) in a human subject, wherein the subject is 6 to 21 years of age and has ≥2 auto-antibodies for T1D, and wherein said pre-T1D is prior to onset of symptoms and requirement for exogenous insulin, the method comprising using a medical device to administer a composition comprising at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37, wherein said device is suitable for subcutaneously (SC) administering said composition comprising at least one anti-TNF antibody.

### Claim 116 (depends on 114)

The method according to claim 114, wherein the device is suitable for self-administration and the device is selected from the group consisting of: prefilled syringe, prefilled syringe with an ULTRASAFE PASSIVE® (needle guard), and a VARIOJECT™ (injector).

### Claim 117 (depends on 115)

The method according to claim 115, wherein the device is the VARIOJECT™ (injector) with a 4.5 mm needle length.

### Claim 118

A pharmaceutical composition for the treatment or prevention of Type I Diabetes, comprising an isolated mammalian anti-TNF antibody or fragment thereof having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37, or fragment thereof and at least one pharmaceutically acceptable carrier or diluent.

### Claim 119

A method for treating pre-Type 1 Diabetes (pre-T1D) in a human subject, wherein the subject is about 6 to 21 years of age and has about ≥2 auto-antibodies for T1D, wherein said pre-T1D is prior to onset of symptoms and requirement for exogenous insulin, the method comprising administering to the subject an anti-TNF antibody having a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO:36 and a light chain (LC) comprising an amino acid sequence of SEQ ID NO:37, or antigen binding fragment thereof.

### Claim 120

A composition for treatment or prevention of Type I Diabetes comprising at least one isolated mammalian anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 or fragment thereof.
